Published in Eur J Pharm Sci on December 01, 2000
Platelet-mediated metabolism of the common dietary flavonoid, quercetin. PLoS One (2010) 0.98
Oxidant/antioxidant status in obese adolescent females with acne vulgaris. Indian J Dermatol (2009) 0.75
ESPEN Guidelines on Enteral Nutrition: Non-surgical oncology. Clin Nutr (2006) 2.89
Two novel protein-tyrosine kinases, each with a second phosphotransferase-related catalytic domain, define a new class of protein kinase. Mol Cell Biol (1991) 2.47
Mutation position and type of substitution in the beta-subunit of the RNA polymerase influence in-vitro activity of rifamycins in rifampicin-resistant Mycobacterium tuberculosis. J Antimicrob Chemother (1995) 2.22
Selective induction by nerve growth factor of tyrosine hydroxylase and dopamine- -hydroxylase in the rat superior cervical ganglia. Proc Natl Acad Sci U S A (1971) 1.96
Expression of two novel eph-related receptor protein tyrosine kinases in mammary gland development and carcinogenesis. Oncogene (1994) 1.51
In vivo enhancement of tyrosine hydroxylation in rat striatum by tetrahydrobiopterin. Nature (1974) 1.51
Comparative studies on the effect of the nerve growth factor on sympathetic ganglia and adrenal medulla in newborn rats. Brain Res (1972) 1.44
PDPH in obstetric anesthesia: comparison of 24-gauge Sprotte and 25-gauge Quincke needles and effect of subarachnoid administration of fentanyl. Reg Anesth (1993) 1.39
Synthesis and biochemical evaluation of N-(4-phenylthiazol-2-yl)benzenesulfonamides as high-affinity inhibitors of kynurenine 3-hydroxylase. J Med Chem (1997) 1.31
Quantitative enzyme radioautography with 3H-Ro 41-1049 and 3H-Ro 19-6327 in vitro: localization and abundance of MAO-A and MAO-B in rat CNS, peripheral organs, and human brain. J Neurosci (1992) 1.30
Functional analysis of an olfactory receptor in Drosophila melanogaster. Proc Natl Acad Sci U S A (2001) 1.28
Pharmacokinetic-pharmacodynamic interaction between the COMT inhibitor tolcapone and single-dose levodopa. Br J Clin Pharmacol (1995) 1.09
Integrated pharmacokinetics and pharmacodynamics of the novel catechol-O-methyltransferase inhibitor tolcapone during first administration to humans. Clin Pharmacol Ther (1995) 1.06
Rapid and sensitive single-step radiochemical assay for catechol-O-methyltransferase. J Neurochem (1982) 1.06
Time course of the development of enzymes involved in the synthesis of norepinephrine in the superior cervical ganglion of the rat from birth to adult life. Brain Res (1972) 1.02
Nicotinamide is a brain constituent with benzodiazepine-like actions. Nature (1979) 1.00
Some basic aspects of reversible inhibitors of monoamine oxidase-A. Acta Psychiatr Scand Suppl (1990) 1.00
[Comparison of the new MAO-A inhibitors moclobemide, brofaromine and toloxatone with tranylcypromine in an animal experiment: significance for clinical practice]. Psychiatr Prax (1989) 0.98
On tyramine, food, beverages and the reversible MAO inhibitor moclobemide. J Neural Transm Suppl (1988) 0.97
Ro 19-6327, a reversible and highly selective monoamine, oxidase B inhibitor: a novel tool to explore the MAO-B function in humans. Adv Neurol (1990) 0.96
Neurochemical profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A. J Pharmacol Exp Ther (1989) 0.95
From moclobemide to Ro 19-6327 and Ro 41-1049: the development of a new class of reversible, selective MAO-A and MAO-B inhibitors. J Neural Transm Suppl (1990) 0.94
Measurement of human cerebral monoamine oxidase type B (MAO-B) activity with positron emission tomography (PET): a dose ranging study with the reversible inhibitor Ro 19-6327. Eur J Clin Pharmacol (1991) 0.93
Multiple-dose clinical pharmacology of the catechol-O-methyl-transferase inhibitor tolcapone in elderly subjects. Eur J Clin Pharmacol (1996) 0.92
Bioavailability of L-dopa after Madopar HBS administration in healthy volunteers. Eur Neurol (1987) 0.92
Local anesthetic myotoxicity: a case and review. Anesthesiology (1994) 0.92
Characterization of a novel murine testis-specific serine/threonine kinase. Gene (1994) 0.92
Optimizing levodopa pharmacokinetics with multiple tolcapone doses in the elderly. Clin Pharmacol Ther (1997) 0.92
Nerve growth factor and preganglionic cholinergic nerves; their relative importance to the development of the terminal adrenergic neuron. Brain Res (1972) 0.91
Molecular characterization of the murine syk protein tyrosine kinase cDNA, transcripts and protein. Biochem Biophys Res Commun (1995) 0.90
Pharmacodynamics of lazabemide, a reversible and selective inhibitor of monoamine oxidase B. Br J Clin Pharmacol (1994) 0.89
Pharmacokinetic-pharmacodynamic interactions between two selective monoamine oxidase inhibitors: moclobemide and selegiline. Clin Neuropharmacol (1996) 0.89
The pharmacology of Parkinson's disease: basic aspects and recent advances. Experientia (1984) 0.89
Structure-based design, synthesis, and in vitro evaluation of bisubstrate inhibitors for catechol O-methyltransferase (COMT). Chemistry (2000) 0.87
Pharmacokinetics of oral moclobemide in healthy human subjects and effects on MAO-activity in platelets and excretion of urine monoamine metabolites. Eur J Clin Pharmacol (1985) 0.86
Ro 40-7592, a novel, very potent, and orally active inhibitor of catechol-O-methyltransferase: a pharmacological study in rats. Adv Neurol (1990) 0.86
iyk, a novel intracellular protein tyrosine kinase differentially expressed in the mouse mammary gland and intestine. Biochem Biophys Res Commun (1995) 0.86
The effect of COMT inhibition by tolcapone on tolerability and pharmacokinetics of different levodopa/benserazide formulations. Eur Neurol (1997) 0.86
Pharmacodynamics of benserazide assessed by its effects on endogenous and exogenous levodopa pharmacokinetics. Br J Clin Pharmacol (1997) 0.85
Success rates in producing sympathetic blockade by paratracheal injection. Clin J Pain (1994) 0.85
Short-acting novel MAO inhibitors: in vitro evidence for the reversibility of MAO inhibition by moclobemide and Ro 16-6491. Naunyn Schmiedebergs Arch Pharmacol (1987) 0.85
Intestinal absorption of levodopa in man. Eur J Clin Pharmacol (1983) 0.85
Neurally mediated control of enzymes involved in the synthesis of norepinephrine; are they regulated as an operational unit? Naunyn Schmiedebergs Arch Pharmakol (1971) 0.85
Preclinical profiles of the novel reversible MAO-A inhibitors, moclobemide and brofaromine, in comparison with irreversible MAO inhibitors. J Neural Transm Suppl (1989) 0.84
Pharmacology of moclobemide. Clin Neuropharmacol (1993) 0.84
Expression of functional membrane-bound and soluble catechol-O-methyltransferase in Escherichia coli and a mammalian cell line. J Neurochem (1992) 0.83
Effects of tolcapone, a novel catechol-O-methyltransferase inhibitor, on striatal metabolism of L-dopa and dopamine in rats. Eur J Pharmacol (1995) 0.83
Pharmacokinetics and pharmacodynamics after oral and intravenous administration of tolcapone, a novel adjunct to Parkinson's disease therapy. Eur J Clin Pharmacol (1998) 0.83
Simultaneous determination of histamine and N alpha-methylhistamine in biological samples by an improved enzymatic single isotope assay. Agents Actions (1985) 0.82
Inhibition of decarboxylase and levels of dopa and 3-O-methyldopa: a comparative study of benserazide versus carbidopa in rodents and of Madopar standard versus Madopar HBS in volunteers. Eur Neurol (1987) 0.82
Mode of action and characteristics of monoamine oxidase-A inhibition by moclobemide. Psychopharmacology (Berl) (1992) 0.82
Effect of selective and reversible MAO inhibitors on dopamine outflow in rat striatum: a microdialysis study. J Neural Transm Suppl (1990) 0.81
Biochemistry and pharmacology of moclobemide, a prototype RIMA. Psychopharmacology (Berl) (1992) 0.80
Species differences in changes of heart monoamine oxidase activities with age. J Neural Transm Suppl (1994) 0.78
Radioenzymatic assay of femtomole concentrations of DOPA in tissues and body fluids. J Neurochem (1979) 0.78
L-cycloserine: behavioural and biochemical effects after single and repeated administration to mice, rats and cats. Neuropharmacology (1986) 0.78
Lazabemide (Ro 19-6327), a reversible and highly sensitive MAO-B inhibitor: preclinical and clinical findings. J Neural Transm Suppl (1994) 0.78
Current density and conductivity dependent electroporation of Escherichia coli C600. Prog Biophys Mol Biol (2012) 0.77
Molecular neuroanatomy of MAO-A and MAO-B. J Neural Transm Suppl (1990) 0.77
Immunoaffinity purification and partial amino acid sequence analysis of catechol-O-methyltransferase from pig liver. Biochim Biophys Acta (1991) 0.76
Pre-clinical pharmacology of moclobemide. A review of published studies. Br J Psychiatry Suppl (1989) 0.75
Monoclonal antibodies recognizing both soluble and membrane bound catechol-O-methyltransferase. J Neural Transm Suppl (1990) 0.75
Benzodiazepine receptor: localization by photoaffinity labeling and isolation of a possible endogenous ligand. Adv Biochem Psychopharmacol (1980) 0.75
The cardiovascular effects of the antihypertensive drug debrisoquin: A contribution to the pharmacology of chronic treatment. III. Absence of adrenergic degeneration after 8-week administration to dogs. J Pharmacol Exp Ther (1978) 0.75
Clinical, pharmacokinetic, and pharmacodynamic effects of tolcapone withdrawal in levodopa-treated patients with parkinsonism. Clin Neuropharmacol (2000) 0.75
Interaction of moclobemide and tricyclic antidepressants with the tyramine pressor effect in rats. Psychopharmacology (Berl) (1992) 0.75
Ro 16-6491: a new reversible and highly selective MAO-B inhibitor protects mice from the dopaminergic neurotoxicity of MPTP. Adv Neurol (1987) 0.75
Mosé Da Prada and the discovery of tolcapone. J Neural Transm Suppl (1998) 0.75
The effects of lifelong treatment with MAO inhibitors on amino acid levels in rat brain. J Neural Transm Park Dis Dement Sect (1990) 0.75
Absence of degeneration of adrenergic neurones after prolonged treatment of newborn rats with debrisoquin. Acta Pharmacol Toxicol (Copenh) (1975) 0.75
Monitoring induced gene expression of single cells in a multilayer microchip. Anal Bioanal Chem (2011) 0.75
Reversible, enzyme-activated monoamine oxidase inhibitors: new advances. Pharmacol Res Commun (1988) 0.75
Interactions of the novel inhibitors of MAO-B Ro 19-6327 and Ro 16-6491 with the active site of the enzyme. Pharmacol Res Commun (1988) 0.75
Tyramine content of preserved and fermented foods or condiments of Far Eastern cuisine. Psychopharmacology (Berl) (1992) 0.75
Short-lasting and reversible inhibition of monoamine oxidase-A by moclobemide. Acta Psychiatr Scand Suppl (1990) 0.75
Absence of degeneration of adrenergic neurons after prolonged treatment with debrisoquin. J Pharmacol Exp Ther (1974) 0.75
Neurochemical effects in vitro and in vivo of the antidepressant Ro 11-1163, a specific and short-acting MAO-A inhibitor. Mod Probl Pharmacopsychiatry (1983) 0.75
Pharmacokinetics and pharmacodynamics of single and multiple doses of the MAO-B inhibitor lazabemide in healthy subjects. Br J Clin Pharmacol (1997) 0.75
Radioautographic evidence that the GABAA receptor antagonist SR 95531 is a substrate inhibitor of MAO-A in the rat and human locus coeruleus. Eur J Neurosci (1994) 0.75
Characteristics of procarbazine as an inhibitor in-vitro of rat semicarbazide-sensitive amine oxidase. J Pharm Pharmacol (1992) 0.75
Uptake, metabolism and subcellular localization of MPTP and MPP+ in blood platelets. Clin Neuropharmacol (1986) 0.75
Tyrosine kinases: from viral oncogenes to developmental regulators. Behring Inst Mitt (1991) 0.75
[Psychotherapy for children and adolescents at the Institute for Psychogenic Diseases of the National Health Insurance in Berlin]. Prax Kinderpsychol Kinderpsychiatr (1977) 0.75
Conversion of the neurotoxic precursor 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine into its pyridinium metabolite by human platelet monoamine oxidase type B. Neurosci Lett (1985) 0.75
Resolution, EPC-syntheses, absolute stereochemistry, and pharmacology of the (S)-(+)- and (R)-(-)-isomers of the MAO-A inhibitor tetrindole hydrochloride. Arch Pharm (Weinheim) (1996) 0.75